MoonLake Immunotherapeutics (MLTX) Cash & Current Investments (2020 - 2026)

MoonLake Immunotherapeutics' Cash & Current Investments history runs 7 years deep, the most recent figure standing at $357.9 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 25.45% year-over-year to $357.9 million; the TTM figure through Mar 2026 stood at $357.9 million (down 25.45% YoY), while the FY2025 annual figure was $394.0 million, down 12.07% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $357.9 million, down from $394.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $547.1 million in Q1 2024, with the low at $63.0 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $436.6 million (2024), against an average of $367.2 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments soared 8533.99% in 2022, then plunged 37.61% in 2023.
• MoonLake Immunotherapeutics' Cash & Current Investments stood at $72.1 million in 2022, then soared by 608.6% to $511.0 million in 2023, then slipped by 12.32% to $448.0 million in 2024, then retreated by 12.07% to $394.0 million in 2025, then fell by 9.15% to $357.9 million in 2026.
• Business Quant data shows MLTX's Cash & Current Investments at $357.9 million in Q1 2026, $394.0 million in Q4 2025, and $380.5 million in Q3 2025.